Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Alzheimer's brains commonly have many neurons with more DNA and genomic copies of APP gene

Scientists at The Scripps Research Institute have found diverse genomic changes in single neurons from the brains of Alzheimer's patients, pointing to an unexpected factor that may underpin the most common form of the disease.

5 Feb 2015

Can-Fite BioPharma completes patient enrollment in CF101 Phase II/III psoriasis trial

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that all patients enrolled in its Phase II/III psoriasis trial for the Company's drug candidate CF101 have completed the study's 32 week treatment protocol.

4 Feb 2015

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen today announced a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira® (adalimumab) in patients with moderate-to-severe rheumatoid arthritis met its primary and key secondary endpoints.

4 Feb 2015

New study helps explain how booster shots trigger immune 'memory' to improve

The last time you were in the doctor's office for a vaccine booster shot, did you wonder why you needed one? Exactly how booster shots offer long-term protection from viruses has long been a mystery to scientists.

3 Feb 2015

TSRI researchers awarded grant to develop novel method for detecting DNA damage in stem cells

A team at The Scripps Research Institute has won a $1,784,000 grant from the California Institute for Regenerative Medicine (CIRM). The funding will support the development of a new method for detecting DNA damage in stem cells to ensure that only the highest quality cells are used in transplantation or therapy.

31 Jan 2015

Blood tests for Chikungunya virus and rheumatoid arthritis could produce similar results

A mosquito-borne virus that has spread to the Caribbean and Central and South America and has caused isolated infections in Florida often causes joint pain and swelling similar to that seen in patients with rheumatoid arthritis.

31 Jan 2015

ANI Pharmaceuticals launches Etodolac 300mg oral capsules

ANI Pharmaceuticals, Inc. today announced the launch of Etodolac 300mg oral capsules, indicated for use in the management of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and acute pain.

30 Jan 2015

Preventing obesity-related inflammation may reverse type 2 diabetes

Preventing inflammation in obese fat tissue may hold the key to preventing or even reversing type 2 diabetes, new research has found.

28 Jan 2015

TSRI scientists identify novel synthetic compound that reduces activity of a cancer-related protein

Scientists from the Florida campus of The Scripps Research Institute have identified a novel synthetic compound that sharply inhibits the activity of a protein that plays an important role in in the progression of breast and pancreatic cancers.

15 Jan 2015

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody ("mAb") targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea.

14 Jan 2015

Major investment boosts Scotland's gene research

A major investment in gene sequencing technology will secure Scotland's place as a world leader in a genomics revolution that is set to transform healthcare.

14 Jan 2015

EMA accepts Praluent (alirocumab) MAA for review

Regeneron and Sanofi today announced that the European Medicines Agency has accepted for review the Marketing Authorization Application for Praluent (alirocumab). Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) that is intended for the treatment of patients with hypercholesterolemia.

12 Jan 2015

LJI researcher awarded $1.6 million grant to study factors that trigger onset of type 1 diabetes

The American Diabetes Association has awarded La Jolla Institute researcher Stephanie Stanford, Ph.D., a $1.6 million grant to investigate the genetic and environmental factors that trigger the onset of type 1 diabetes.

11 Jan 2015

Two new ODYSSEY trials meet primary efficacy endpoints

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that two new ODYSSEY trials, which are the first Phase 3 trials to assess alirocumab administered every four weeks, met their primary efficacy endpoints.

9 Jan 2015

Enzymes linked to diabetes, obesity play major roles in arthritis and leukemia

Enzymes linked to diabetes and obesity appear to play key roles in arthritis and leukemia, potentially opening up new avenues for treating these diverse diseases, according to new research at Washington University School of Medicine in St. Louis.

8 Jan 2015

Using HIV drugs to treat AMD: an interview with Dr Mark Young

NRTIs are compounds which were originally developed in the 1960s as anti-cancer agents. They are similar in structure to the bases which make up DNA, and it was hoped that they would interfere with DNA replication in fast-growing cancer cells, slowing down or stopping tumour growth.

7 Jan 2015

Can-Fite BioPharma completes RA Phase III study of lead drug candidate CF101

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it completed the design of the Rheumatoid Arthritis (RA) Phase III study of its lead drug candidate CF101.

31 Dec 2014

Offspring of mice treated with drug had delayed onset, reduced symptoms of Huntington's disease

Famine, drug abuse and even stress can "silence" certain genes, causing health problems in generations to come. Now scientists are wondering—could therapies that change gene expression in parents help their children?

23 Dec 2014

Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has dosed the first patient in a Phase II trial for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

22 Dec 2014

Scientists identify white blood cells that tumors use to suppress disease-fighting immune system

A study led by St. Jude Children's Research Hospital scientists has identified the population of white blood cells that tumors use to enhance growth and suppress the disease-fighting immune system.

19 Dec 2014

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Alzheimer's brains commonly have many neurons with more DNA and genomic copies of APP gene

Can-Fite BioPharma completes patient enrollment in CF101 Phase II/III psoriasis trial

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

New study helps explain how booster shots trigger immune 'memory' to improve

TSRI researchers awarded grant to develop novel method for detecting DNA damage in stem cells

Blood tests for Chikungunya virus and rheumatoid arthritis could produce similar results

ANI Pharmaceuticals launches Etodolac 300mg oral capsules

Preventing obesity-related inflammation may reverse type 2 diabetes

TSRI scientists identify novel synthetic compound that reduces activity of a cancer-related protein

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

Major investment boosts Scotland's gene research

EMA accepts Praluent (alirocumab) MAA for review

LJI researcher awarded $1.6 million grant to study factors that trigger onset of type 1 diabetes

Two new ODYSSEY trials meet primary efficacy endpoints

Enzymes linked to diabetes, obesity play major roles in arthritis and leukemia

Using HIV drugs to treat AMD: an interview with Dr Mark Young

Can-Fite BioPharma completes RA Phase III study of lead drug candidate CF101

Offspring of mice treated with drug had delayed onset, reduced symptoms of Huntington's disease

Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Scientists identify white blood cells that tumors use to suppress disease-fighting immune system

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in